|
|
|
|
|
Bawaskar,H. S.. |
Snake antivenom is a specific antidote to the venom action, neutralizing the circulating venom. However, it fails to neutralize the venom fixed to target organs such as platelets, renal tubules, etc. Russell's viper venom initiates rapid coagulation in a victim by activating blood platelets, factors V, X, and anticoagulant cofactors. Activation of thrombin, resulting in formation of micro-thrombi, fibrinolysis, and a vicious cascade, sets in. Inhibition of activated platelets by aspirin (cyclooxygenase inhibitor) and clopidogrel (ADP receptor inhibitor) helps to break this vicious circle induced by Russell's venom and may initiate the natural physiological clotting mechanism. They can be utilized as an adjuvant treatment. |
Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Russell's viper; Coagulation; Fibrinolysis; Aspirin; Clopidogrel. |
Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992006000100011 |
| |
|
|
Marchini,J.F.M.; Pinto,M.R.; Novaes,G.C.; Badran,A.V.; Pavão,R.B.; Figueiredo,G.L.; Lago,I.M.; Lima-Filho,M.O.; Lemos,D.C.; Tonani,M.; Antloga,C.M.; Oliveira,L.; Lorenzi,J.C.; Marin-Neto,J.A.. |
Clopidogrel and aspirin are the most commonly used medications worldwide for dual antiplatelet therapy after percutaneous coronary intervention. However, clopidogrel hyporesponsiveness related to gene polymorphisms is a concern. Populations with higher degrees of genetic admixture may have increased prevalence of clopidogrel hyporesponsiveness. To assess this, we genotyped CYP2C19, ABCB1, and PON1 in 187 patients who underwent percutaneous coronary intervention. Race was self-defined by patients. We also performed light transmission aggregometry with adenosine diphosphate (ADP) and arachidonic acid during dual antiplatelet therapy. We found a significant difference for presence of the CYP2C19*2 polymorphism between white and non-white patients. Although 7%... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Platelet function tests; Single nucleotide polymorphism; Percutaneous coronary intervention; Aspirin; Clopidogrel. |
Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000100702 |
| |
|
|
|